Related Experiment Videos
Synergistic Activity of Venetoclax and Rituximab in Multiply Relapsed or Refractory Waldenström Macroglobulinaemia
Angeline Josiah1,2, Ryan Low1, Alisha Ganesh1
1Concord Repatriation General Hospital Sydney Australia.
Introduction:
There are limited options for multiply relapsed/refractory (R/R) Waldenström Macroglobulinaemia (WM) post Bruton tyrosine kinase inhibitors (BTKi). The synergy of venetoclax and rituximab (Ven-R) may improve the poor outcomes with venetoclax monotherapy.
Methods:
A retrospective analysis was conducted of four patients treated with Ven-R.
Results:
All patients were refractory to covalent BTKi and had received 4-7 prior therapies. Three patients achieved a very good partial response. Treatment was lifesaving in one, facilitating reduction in plasmapheresis and improved cytopenias.
Conclusion:
We demonstrate meaningful responses to Ven-R in R/R WM, supporting a rationale for prospective clinical trials of this combination.
Trial Registration:
The authors have confirmed clinical trial registration is not needed for this submission.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers